期刊文献+

连续肾脏替代治疗对脓毒症炎症因子清除作用的研究进展 被引量:4

Advances in Continuous Renal Replacement Therapy for Clearance of Inflammatory Cytokines in Sepsis
下载PDF
导出
摘要 连续肾脏替代治疗(continuous renal replacement therapy,CRRT)是治疗脓毒症的主要方式之一,结合血液透析原理,能够有效地清除激活全身炎症反应的炎症介质、内毒素及细胞因子、补体、炎症细胞等,阻止脓毒症的发生与进展。国内外的大量研究已证实CRRT治疗脓毒症的高效性,但目前尚无可靠的生物标志物来评估其对脓毒症炎性因子的清除作用及预后。文章通过分析近年来CRRT治疗脓毒症的相关文献,总结不同炎性因子的表达特点以及脓毒症患者炎症反应的进展过程,深入了解CRRT对不同炎性因子的清除作用,以期进一步明确CRRT对脓毒症的治疗效果,从而为临床危重病中CRRT的应用提供理论基础。 Continuous renal replacement therapy(CRRT)is one of the main methods for the treatment of sepsis.Combined with the principle of hemodialysis,it can effectively remove inflammatory mediators,endotoxins,cytokines,complements and inflammatory cells to prevent the occurrence and progression of sepsis.A large number of studies have confirmed the effectiveness of CRRT in the treatment of sepsis.However,there is no reliable biomarker to evaluate the efficacy and prognosis of CRRT for clearance of inflammatory factors.In order to clarify the therapeutic effect of CRRT on sepsis and provide a theoretical basis for clinical application of CRRT in critical patients,we analyze the recent literature on the treatment of sepsis with CRRT to summarize the expression characteristics of different inflammatory factors and the progress of inflammatory response and to further understand the scavenging effect of CRRT on inflammatory factors.
作者 孟楠 修光辉 李冰沁 凌斌 MENG Nan;XIU Guang-Hui;LI Bing-qin;LING Bin(Department of the Intensive Care Unit,the Fourth Hospital Affiliated to Kunming Medical University,Kunming 650021,China)
出处 《实用临床医学(江西)》 CAS 2020年第1期95-98,共4页 Practical Clinical Medicine
基金 国家自然科学基金面上项目(81360289) 云南省科技厅-昆明医科大学联合专项重点项目[2017FE468(-180)] 云南省高层次卫生计生技术人才培养项目(H-2017060) 徐俊专家工作站(2017IC025)。
关键词 连续肾脏替代治疗 脓毒症 炎症因子 清除作用 continuous renal replacement therapy sepsis inflammatory cytokines clearance effect
  • 相关文献

参考文献3

二级参考文献26

  • 1Bone RC,Balk RA,Cerra FB. ACCP/SCCM definitions for sepsis and organ failure guidelines for the use of innovative therapies in sepsis[J]. Chest, 1992,101:1644- 1655.
  • 2Joan M. The role of C reactive protein in the evaluation and management of infants with suspected sepsis[J].Adv Neonatal Care,2003,3(1):3 -13.
  • 3Povoa P, Almeida E, Moreira P,et al. C-reactive protein as an in dicator of sepsis[J]. Intensive Care Med, 2008, 24: 1052-1056.
  • 4Claeys R,Vinken S,Spapen H,etal. Plasma procalcitonin and C- reactive protein in acute septic shock: clinical and biological corerlates[J]. Crit Care Med, 2002,30(4) :757-762.
  • 5Haweky PM. Mechanisms of resistance to antibiotics[J]. In tensiev Caer Med, 2000,26 : 9 -13.
  • 6Hosokawa K, Gaspard N, Su F, et al. Clinical neurophysiological assessment of sepsis-associated brain dysfunction: a systematic reviewCj]. Crit Care, 2014;18(6):674.
  • 7Alsolamy S, Salamah AM, Thagafi AM, et al. Diagnostic accuracy of a screening electronic alert tool for severe sepsis and septic shock in the emergency department[j]. BMC Med Inform Decis Mak, 2014; 14(1) : 105.
  • 8Palmi ere C, Bardy D,Mangi n P, et al. Value of sTREM-1, procalcitonin and CRP as laboratory parameters for postmortem diagnosis of sepsis[J].J Infect, 2013:67(6):545-555.
  • 9Liew YX,Chlebicki MP, Lee W, et al. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP)[J]. Eur J Clin Microbiol Infect Dis, 2011;30¢7):853-855.
  • 10KokltlS, Tuna Y, Gii 1 sen M T, et al. Long-term Efficacy and safety of lamivudine, entecavir,and tenofovir for treatment of hepatitis B virus-related cirrhosis[J]. Clin Gastroenterol Hepatol, 2013;11(1) :88-94.

共引文献298

同被引文献42

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部